SYMBIOTEC PHARMALAB Latest Share Price (SYMBIOTEC)
TODAY IN ONE LINE
SYMBIOTEC is little changed at ₹1040.55 — a quiet consolidation day.
With a market cap of ₹6,570.19 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SYMBIOTEC PHARMALAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest SYMBIOTEC PHARMALAB News
What changed recently?
Recent events, corporate actions, and announcements.
SYMBIOTEC PHARMALAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SYMBIOTEC PHARMALAB, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SYMBIOTEC PHARMALAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SYMBIOTEC PHARMALAB — derived from the latest tape, not yesterday's close.
SYMBIOTEC PHARMALAB last traded at ₹1,040.55 with an intraday range of ₹1,020.6–₹1,056.45 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1040.55| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1129.50 | +88.95 | +8.55% |
| R3 | 1093.65 | +53.10 | +5.10% |
| R2 | 1075.05 | +34.50 | +3.32% |
| R1 | 1057.80 | +17.25 | +1.66% |
| PIVOT | 1039.20 | -1.35 | -0.13% |
| CURRENT | 1040.55 | — | — |
| S1 | 1021.95 | -18.60 | -1.79% |
| S2 | 1003.35 | -37.20 | -3.58% |
| S3 | 986.10 | -54.45 | -5.23% |
| S4 | 950.25 | -90.30 | -8.68% |
SYMBIOTEC is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1030–₹1050.45
Trading Inside opening range
SYMBIOTEC PHARMALAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SYMBIOTEC PHARMALAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
SYMBIOTEC PHARMALAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,570.19 Cr..
SYMBIOTEC PHARMALAB segment analysis : revenue and profit mix.
Disclosed business segments at SYMBIOTEC PHARMALAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
SYMBIOTEC PHARMALAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SYMBIOTEC PHARMALAB.
Our AI distills the core fundamental drivers supporting SYMBIOTEC PHARMALAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
SYMBIOTEC PHARMALAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SYMBIOTEC PHARMALAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SYMBIOTEC PHARMALAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SYMBIOTEC PHARMALAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SYMBIOTEC PHARMALAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SYMBIOTEC PHARMALAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SYMBIOTEC PHARMALAB stood at 28.1% of traded volume, against a 20-day average of 26.4%.
SYMBIOTEC PHARMALAB announcements: results, concalls, ratings, M&A.
Filings SYMBIOTEC PHARMALAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SYMBIOTEC PHARMALAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 3 documents below.
Insider Trading / SAST
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on…
Board Meeting
Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2026 ,inter alia, to consider…
Insider Trading / SAST
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Beacon…
SYMBIOTEC PHARMALAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SYMBIOTEC PHARMALAB has declared, sequenced by announce and record date.
SYMBIOTEC PHARMALAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SYMBIOTEC PHARMALAB: business, sector, key facts.
What SYMBIOTEC PHARMALAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SYMBIOTEC PHARMALAB is a listed Indian equity.
SYMBIOTEC PHARMALAB
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SYMBIOTEC PHARMALAB (SYMBIOTEC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SYMBIOTEC PHARMALAB (SYMBIOTEC)?
The current share price of SYMBIOTEC PHARMALAB (SYMBIOTEC) is ₹1,040.55. Today, the stock has declined by ₹2.25 (0.22%), trading in a range of ₹1,020.60 to ₹1,056.45. The stock opened at ₹1,040.00 with a trading volume of 2,22,604 shares.
02What is the 52-week high and low price of SYMBIOTEC PHARMALAB stock?
The 52-week high price of SYMBIOTEC PHARMALAB (SYMBIOTEC) is ₹1,193.70, while the 52-week low is ₹934.20. Currently trading at ₹1,040.55, the stock is 11.38% above its 52-week low and 12.83% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of SYMBIOTEC PHARMALAB and when is the next dividend?
SYMBIOTEC PHARMALAB offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,040.55, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is SYMBIOTEC PHARMALAB stock performing today in the market?
SYMBIOTEC PHARMALAB stock opened at ₹1,040.00 and is currently trading at ₹1,040.55, showing a decline of ₹2.25 (0.22%). The intraday high is ₹1,056.45 and low is ₹1,020.60. The trading volume stands at 2,22,604 shares, indicating moderate market participation today.
05What is the market capitalization of SYMBIOTEC PHARMALAB?
SYMBIOTEC PHARMALAB has a market capitalization of ₹6,570.19 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,040.55) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of SYMBIOTEC PHARMALAB?
SYMBIOTEC PHARMALAB has a Return on Equity (ROE) of 0% and Return on Capital Employed (ROCE) of 0%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does SYMBIOTEC PHARMALAB belong to?
SYMBIOTEC PHARMALAB operates in the broader sector and belongs to the its industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the sales and profit growth of SYMBIOTEC PHARMALAB?
SYMBIOTEC PHARMALAB has reported a sales growth of 0% and profit growth of 0%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
The data, ratios and commentary about SYMBIOTEC PHARMALAB (SYMBIOTEC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.